Data investigation
GLP-1 Compounded Pricing Index 2026
What telehealth providers actually charge for compounded semaglutide and tirzepatide — the median, the cheapest and priciest, and the gap to brand-name Wegovy — across the 540+ GLP-1 providers with verified pricing.
This pricing investigation is part of Weight Loss Rankings' living editorial database — 1,160+ research articles and 630+ editorially reviewed GLP-1 telehealth providers, with prices for 540+ of them verified directly against each provider's live page on a monthly cadence.
Compounded GLP-1 medications have rewritten the cash-pay weight-loss market. A year ago, brand-name Wegovy at roughly $1,349/month was the only injectable semaglutide most uninsured Americans could access. Today, 121 of the 638 open GLP-1 telehealth programs we track publish an ongoing month-to-month compounded semaglutide price — and the median of those prices is $179, a 87% discount to brand.
That gap, repeated thousands of times across our dataset, is the single biggest force shaping the consumer GLP-1 market right now. This article puts hard numbers on it: the median, the cheapest and most expensive providers, the distribution shape, and how the savings compare against the brand-name baseline. The data updates every time we verify a provider — so the numbers below are always current as of the timestamp at the top of the page.
Compare vetted GLP-1 providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
No insurance needed · HSA/FSA eligible · vetted by our editors
Ro
FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Starting price: $149/mo (+ required membership)
Get started →Read review Ro →Collective
The lowest flat medication price if you can absorb an annual membership fee
Starting price: $59/mo (+ required membership)
Get started →Read review Collective →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Starting price: $79/mo (“starting at” price)
Get started →Read review CoreAge Rx →Embody
Low flat-rate compounded GLP-1 pricing at every dose
Starting price: $79/mo (sale price)
Get started →Read review Embody →Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Starting price: $129/mo (starting dose)
Get started →Read review Gala →| Provider | Starting price | |
|---|---|---|
7.7Ro | $149/mo (+ required membership) | Get started → |
8.3Collective | $59/mo (+ required membership) | Get started → |
8.3CoreAge Rx | $79/mo (“starting at” price) | Get started → |
7.8Embody | $79/mo (sale price) | Get started → |
8.2Gala | $129/mo (starting dose) | Get started → |
The headline numbers
Across our entire telehealth dataset, here's what people are actually paying per month for compounded semaglutide and tirzepatide— the same active ingredients in Wegovy and Zepbound respectively:
Compounded semaglutide
87% below Wegovy list price ($1,349/mo)
- Cheapest 10%
- $121
- Priciest 10%
- $278
- Prices · programs
- 124 · 121
Compounded tirzepatide
77% below Zepbound list price ($1,086/mo)
- Cheapest 10%
- $149
- Priciest 10%
- $372
- Prices · programs
- 125 · 120
For semaglutide, the median monthly cost is $179. The cheapest 10% of providers charge $121 or less, while the priciest 10% start at $278. That spread — roughly 2× from cheapest to priciest — is much wider than most readers expect, and it's the main reason it's worth comparing providers directly instead of taking the first ad you see at face value.[1]
At the median compounded price, a patient choosing semaglutide saves roughly $2,040 per year versus Wegovy's $349/month self-pay price. For tirzepatide, the median compounded price produces an annual savings of about $2,400 versus Zepbound's $449/month self-pay price (7.5–15 mg). These are real numbers that reset the calculation for anyone whose insurance excludes GLP-1s for obesity (which is most of the privately insured market).[2]
Pricing magnitude — brand vs manufacturer self-pay vs compounded
The cleanest way to see what the cash-pay GLP-1 market looks like right now is to plot every major channel on a single magnitude axis: the brand retail list price, the manufacturer's own self-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound), and the live median compounded monthly cost from our telehealth dataset.
Magnitude comparison
Monthly cash-pay cost (USD/month) across the major GLP-1 channels we track — brand retail list, manufacturer self-pay programs, and live-median compounded telehealth. Compounded medians refreshed November 2026.[2]
- Wegovy — retail list price1,349 USD/moNovo Nordisk WAC baseline
- Saxenda — retail list price1,349 USD/moNovo Nordisk WAC baseline (liraglutide 3 mg)
- Zepbound — retail list price1,086 USD/moEli Lilly WAC baseline
- Mounjaro — retail list price1,112 USD/moEli Lilly WAC baseline (T2D label)
- Ozempic — retail list price1,028 USD/moNovo Nordisk WAC baseline (T2D label)
- Foundayo — retail list price649 USD/moEli Lilly WAC baseline (orforglipron, oral)
- Zepbound — LillyDirect self-pay (7.5–15 mg, 45-day refill)449 USD/moEli Lilly self-pay KwikPen/vial, dose-tiered $299 (2.5 mg) to $699 without the refill offer
- Wegovy — NovoCare self-pay (standard pen)349 USD/moNovo Nordisk self-pay pen tier
- Wegovy — NovoCare self-pay (oral pill 1.5 mg)149 USD/moNovo Nordisk self-pay oral tier
- Compounded tirzepatide — live median (this index)249 USD/mo125 published prices from 120 providers · cheapest 10% of prices $149 · priciest 10% $372
- Compounded semaglutide — live median (this index)179 USD/mo124 published prices from 121 providers · cheapest 10% of prices $121 · priciest 10% $278
Two structural observations from this chart. First, the manufacturer self-pay programs already cut the retail list price by 65–90% — Wegovy NovoCare standard pen at $349/month is a 74% discount to the $1,349 retail list, and the Wegovy oral pill tier at $149/month is an 89% discount. The brand retail list price is no longer the realistic ceiling for a cash-pay patient who is willing to enroll directly with the manufacturer. Second, the compounded channel still sits materially below every brand channel — the live median compounded semaglutide is $179/month vs $149–$299 for the cheapest Wegovy NovoCare tiers, and the cheapest 10% of compounded providers ($121/month) undercuts even the oral Wegovy pill tier.
How prices are distributed
Aggregate medians hide a lot. The histograms below show how the market actually breaks out by price band. Compounded semaglutide skews heavily toward the $100–$200 range, with a long tail of more expensive providers — usually programs that bundle clinical coaching, lab work, or in-network pharmacy guarantees on top of the injection itself.
Compounded semaglutide — monthly price distribution
121 providers · verified November 2026
- <$1007 prices6%
- $100–14926 prices21%
- $150–19953 prices43%
- $200–29932 prices26%
- $300–4996 prices5%
- $500–9990%
- $1,000+0%
Compounded tirzepatide — monthly price distribution
120 providers · verified November 2026
- <$1000%
- $100–14917 prices14%
- $150–19919 prices15%
- $200–29963 prices50%
- $300–49925 prices20%
- $500–9991 price1%
- $1,000+0%
Tirzepatide's distribution sits noticeably higher. There are two reasons: tirzepatide's active pharmaceutical ingredient is more expensive at the wholesale level, and the FDA only removed it from the official drug shortage list in late 2024, which constrained the number of 503A pharmacies legally allowed to compound it during most of 2024.[3]
The cheapest providers right now
The most useful number for most readers isn't the median — it's the actual list of providers at the cheapest end. These update live from our verified dataset:
Cheapest compounded semaglutide
- 1.Mondae$87/mo
- 2.altRX$89/mo
- 3.FeelGood$89/mo
- 4.Mint Med$89/mo
- 5.YourEra$89/mo
Cheapest compounded tirzepatide
- 1.Mint Med$119/mo
- 2.Mondae$126/mo
- 3.Eden$129/mo
- 4.NexLife$129/mo
- 5.OurView Health$129/mo
These lists rank each provider's ongoing month-to-month price, not its first-month introductory deal, prepaid multi-month average or microdose plan. Always read the fine print on whether the rate rises with the dose and whether the listed price includes shipping, the consult, and the medication itself, or whether some of those are billed separately. Our individual side-by-side comparisons normalize for these differences.
Why the spread is so wide
A $121–$278 range for what is, at the molecular level, the same drug raises an obvious question: what are buyers in the higher tier actually paying for? Five things, in our experience working through provider data:
- Sourcing quality. The 503A pharmacies that supply compounded semaglutide vary in size, accreditation, and quality systems. Some publish their certificates of analysis on every batch; others won't share them at all. Providers that source from PCAB-accredited or NABP VPP facilities often charge more.[4]
- Bundled clinical care. The cheapest providers tend to be pure prescription delivery — a 5-minute async intake and the medication mailed out. The mid-tier programs include ongoing physician check-ins, dose titration support, and side- effect management. The most expensive include lab work, dietitian access, or in-app coaching.
- Brand-name fulfillment guarantees. A handful of providers will switch you to brand-name Wegovy (at brand-name prices) if compounded supply is interrupted. This is rare and usually buried in the fine print.
- State availability. Compounding rules differ state to state. Providers licensed in all 50 states have higher compliance overhead than ones operating in 20.
- Marketing and CAC. Some of the spread is just customer acquisition cost. Heavily advertised brands have to recover what they pay to win each new sign-up through higher monthly prices or longer minimum commitments.
None of these inherently make the more expensive provider a worse deal — but they do mean that comparing on price alone misses the story. Our individual ranked best-of lists score on six dimensions (value, effectiveness, UX, trust, accessibility, support) precisely because price is just one input.
How the gap to brand has evolved
The market's 2024 trajectory is well documented in the sources below; our index's published monthly record begins April 2026. In early 2024, at that point, brand-name Wegovy was effectively unavailable to most uninsured patients — supply constraints meant pharmacies routinely ran out, and the cash price hovered near $1,349 when it could be filled at all. The compounded market existed but was concentrated among a small number of telehealth players.[5]
Two things changed that. First, the FDA's formal drug shortage designation for semaglutide gave 503A pharmacies clear legal cover to compound it. That brought dozens of new entrants into the market and pushed prices down through ordinary competition. Second, supply of the brand products and of compounding ingredients grew through 2024 and 2025 as shortages eased. The combination is why the median sits where it sits today rather than where it sat 18 months ago.[6]
Our own index now shows that directly. The table below is our month-by-month record — each row is the verified state of the market at that month's close, computed from every published pricing tier in the database at the time, using the same methodology as the live figures above. Latest snapshot: November 2026. For the geographic companion to these prices — NPI-verified clinic counts and telehealth coverage in every state — see our GLP-1 care access by state dataset.
| Month | Semaglutide median /mo | Tirzepatide median /mo | Providers | Prices measured |
|---|---|---|---|---|
| April 2026 | $184 | $297 | 184 | 242 |
| May 2026 | $179 | $249 | 298 | 442 |
| June 2026 | $175 | $249 | 471 | 657 |
| July 2026 | $175 | $249 | 550 | 756 |
| November 2026 | $179 | $249 | 241 | 249 |
The index is an open panel — month-over-month medians reflect both price changes and new providers entering coverage. To separate the two, we also compute a matched panel: among the 100 providers tracked continuously since April 2026, the median semaglutide price moved $189 → $179 (-5%), and among 77 tirzepatide providers, $297 → $295 (-1%). Much of the open-panel decline in tirzepatide reflects cheaper new entrants joining the index rather than incumbent providers cutting prices.
The three-month observation: same-provider prices have been broadly stable — semaglutide drifting a few percent lower, tirzepatide essentially flat — while the cheapest end of the market sits at $87–$119/month. Brand-name Wegovy and Zepbound, meanwhile, have started offering their own cash-pay programs at roughly half their old retail price as the manufacturers chase share. The gap has narrowed, but it's still meaningful — and for the median patient on the median compounded plan, the savings are still measured in five figures per year.
Methodology
Every price in this index is taken from the public-facing website of the named provider. We re-verify each provider on a rolling basis; the “data as of” stamp at the top of this page reflects the most recent verification across the dataset.
Where a provider lists both an introductory price and an ongoing rate, we use the ongoing rate as the comparable monthly cost: an introductory price lasts a month or two, and the ongoing rate is what a patient pays for the rest of treatment. Prepaid multi-month plan averages, microdose plans and prices that require a separate membership on top are excluded, so every price compared is a like-for-like month-to-month price. Brand-name comparison baselines come from the manufacturer cash-pay list prices for Wegovy and Zepbound as published by Novo Nordisk and Eli Lilly respectively.
Percentile calculations use linear interpolation between the two surrounding ranks (the same convention as Excel'sPERCENTILE function and NumPy's default). The computation is described in full on our methodology page.
Cite this data — November 2026
Free to cite with a linkOriginal analysis of published GLP-1 prices across every telehealth provider in our database. Figures update automatically each month.
Key findings (copy to cite)
- Weight Loss Rankings tracks compounded GLP-1 pricing across 540+ GLP-1 telehealth providers as of November 2026. (Source: Weight Loss Rankings GLP-1 Compounded Pricing Index, https://www.weightlossrankings.org/research/glp1-pricing-index, November 2026)
- Among the 100 providers tracked continuously since April 2026, the median compounded semaglutide price moved $189 to $179/month (-5%); among the 77 continuously-tracked tirzepatide providers, the median moved $297 to $295/month (-1%). Across ALL tracked prices (an open panel that grew from 184 to 241 provider listings over the window, mostly cheaper new entrants), the medians moved $184 to $179 (semaglutide) and $297 to $249 (tirzepatide). (Source: Weight Loss Rankings GLP-1 Compounded Pricing Index, https://www.weightlossrankings.org/research/glp1-pricing-index, November 2026)
- Compounded semaglutide: the median published price is $179/month across 124 published prices from 121 providers (cheapest 10% of prices at or below $121, priciest 10% from $278); the median provider ENTRY price — each provider's cheapest tier — is $179/month. Prices are ongoing month-to-month rates: first-month promotions, prepaid multi-month averages, microdose plans and prices that require a separate membership are excluded. (Source: Weight Loss Rankings GLP-1 Compounded Pricing Index, https://www.weightlossrankings.org/research/glp1-pricing-index, November 2026)
- Compounded tirzepatide: the median published price is $249/month across 125 published prices from 120 providers; the median provider entry price is $248/month. Prices are ongoing month-to-month rates: first-month promotions, prepaid multi-month averages, microdose plans and prices that require a separate membership are excluded. (Source: Weight Loss Rankings GLP-1 Compounded Pricing Index, https://www.weightlossrankings.org/research/glp1-pricing-index, November 2026)
- At the median, compounded semaglutide costs 87% less than brand-name Wegovy's $1,349/month list price, and about $2,040 per year less than Wegovy's $349/month self-pay price. (Source: Weight Loss Rankings GLP-1 Compounded Pricing Index, https://www.weightlossrankings.org/research/glp1-pricing-index, November 2026)
Statistical notes
- Prices are ongoing month-to-month drug prices (the provider's monthly_cost, never a first-month promotion); prepaid multi-month averages, microdose plans and prices that require a separate membership are excluded.
- Each published price is weighted equally; the index is not volume-weighted. Two estimators are published: the per-price (offer) median and the per-provider entry-price median.
- Coverage: the 638 open US GLP-1 telehealth programs in our directory (not pharmacies, apps, supplements or in-person clinics); a program contributes only when it publishes a canonical price and the Price Transparency Index does not disqualify its headline figure. Percentiles use linear interpolation.
- Questions or corrections: see our contact page (/contact) and methodology (/methodology).
Free for editorial use. Please credit Weight Loss Rankings with a link to weightlossrankings.org/research/glp1-pricing-index.
Embed this widget
Free for editorial useDrop our live price-distribution charts into your article or newsletter — the full compounded GLP-1 market at a glance, with the median trend. Pulls fresh data on every render; attribution built in.
<iframe src="https://www.weightlossrankings.org/embed/price-distribution" width="720" height="1160" frameborder="0" style="border:1px solid #e5e7eb;border-radius:12px;max-width:100%" title="Compounded GLP-1 price distribution by Weight Loss Rankings" loading="lazy" ></iframe>
Republishing the data without the iframe? Please credit Weight Loss Rankings with a link to weightlossrankings.org/research/glp1-pricing-index.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- FDA Drug Shortage List · Insurance and regulatory
Frequently Asked Questions
References
- 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 2.Kaiser Family Foundation. Out-of-Pocket Spending and Affordability for GLP-1 Drugs Among Medicare Beneficiaries. KFF Issue Brief. 2024. https://www.kff.org/medicare/issue-brief/out-of-pocket-spending-and-affordability-for-glp-1-drugs-among-medicare-beneficiaries/
- 3.U.S. Food and Drug Administration. FDA Removes Tirzepatide From the Drug Shortage List — Updates and Compounding Guidance. FDA Drug Shortages Database. 2024. https://www.fda.gov/drugs/drug-shortages
- 4.Pharmacy Compounding Accreditation Board (PCAB). Standards for Compounded Sterile Preparations and 503A Facility Accreditation. PCAB / Accreditation Commission for Health Care. 2023. https://www.achc.org/pcab/
- 5.Whitley HP, Trujillo JM, Neumiller JJ. Special Report: Potential Strategies for Addressing GLP-1 Receptor Agonist Shortages. Clin Diabetes. 2023. PMID: 37456085.
- 6.Mahase E. GLP-1 shortages will not resolve this year, EMA warns, amid concern over off-label use. BMJ. 2024. PMID: 38942431.
Related research
GLP-1 Price Transparency Index 2026
We checked what every open GLP-1 telehealth program's advertised monthly price covers. 471 of 638 advertise a figure that is not what you pay: entry tiers, first-month rates, prepays or drug-excluded memberships.
7 min read
FDA Warning Letters to Compounded GLP-1 Telehealth Providers: The Live Investigation
A tracked set of FDA warning letters to compounded GLP-1 telehealth providers and compounding pharmacies, with the violation patterns, most-cited statutes, and issuing offices, and which business models should make you cautious. The dataset is rebuilt from the FDA's public index.
10 min read
How Compounded GLP-1 Prices Moved Over 16 Months: Provider-by-Provider Trajectories
We tracked monthly cash prices for compounded semaglutide across the largest telehealth providers from January 2025 onward. Every provider in our tracked set has cut prices — but at very different rates, with the biggest movers converging on a $199 floor.
10 min read
Is $99 Compounded Semaglutide Real? We Verified Every Provider at the Floor Price
Multiple telehealth providers advertise compounded semaglutide at $99 per month — well below the market median. We verified the licensing, pharmacy partner, dose, and total monthly cost for each one.
9 min read
GLP-1 & Weight Loss Care Access by State (2026)
State-by-state data on 31,083 NPI-verified obesity, endocrinology and bariatric clinics: clinics per 100,000 residents, telehealth coverage, the cheapest compounded semaglutide and tirzepatide prices, and a Care Gap Index.
9 min read
GLP-1 Insurance Coverage at the 10 Largest US Insurers: A 2026 Audit
Does your insurance cover Wegovy or Zepbound? We audited the 10 largest US health insurers — covering more than 460 million members combined — and the answer is the same everywhere: technically yes, but every plan requires prior authorization and coverage is plan-specific.
9 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →Pricing Compare
Get started →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Read full review →Pricing Compare
Get started →Pricing Compare
Get started →